![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluation of Pharmacokinetic Drug-Drug Interaction (DDI) Between BMS-791325, an NS5B Non-Nucleoside
Polymerase Inhibitor, Daclatasvir and Asunaprevir in Triple Combination in HCV Genotype 1-Infected Patients
|
|
|
Reported by Jules Levin
EASL Amsterdam April 25, 2013
Wang X, Li W, Huang S-P, He B, Chung E, Griffies A, Cooney E, Hughes EA, Kandoussi H, Sims K, Gardiner D, Bertz RJ, Eley T
Bristol-Myers Squibb, Princeton, NJ, USA
![EASL1.gif](../images/042513/042513-2/EASL1.gif)
![EASL2.gif](../images/042513/042513-2/EASL2.gif)
![EASL3.gif](../images/042513/042513-2/EASL3.gif)
![EASL4.gif](../images/042513/042513-2/EASL4.gif)
![EASL5.gif](../images/042513/042513-2/EASL5.gif)
![EASL6.gif](../images/042513/042513-2/EASL6.gif)
![EASL7.gif](../images/042513/042513-2/EASL7.gif)
![EASL8.gif](../images/042513/042513-2/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|